Chemotherapy compliance, tolerance and efficacy in elderly and non-elderly patients with metastatic colorectal cancer: A single institution comparative study

Journal of B.U.ON.

Volumn 18, Issue 3, 2013, Pages 629-634

  Bakogeorgos, M ^a   Mountzios, Giannis ^a   Kotsantis, G ^a   Economopoulou, P ^a   Fytrakis, N ^a   Kentepozidis, N ^a  

^a IASO GENERAL HOSPITAL   (Greece)

Author keywords

Chemotherapy; Compliance; Elderly patients; Metastatic colorectal cancer; Toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; CAPECITABINE; FLUOROURACIL; IRINOTECAN; OXALIPLATIN;

ADULT; AGED; ANEMIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; GERIATRIC PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; NEUTROPENIA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; FEMALE; FLUOROURACIL; FOLLOW-UP STUDIES; HUMANS; LEUCOVORIN; MALE; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM METASTASIS; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84885726509     PISSN: 11070625     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Khasraw K, Marx G. Chemotherapy in the elderly. Cancer Forum 2008;32:131-152.
2. Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer 1997;80:1273-1283. (Pubitemid 27407230)
3. Yancik R, Ries LA. Aging and cancer in America: demographic and epidemiologic perspectives. Hematol Oncol Clin North Am 2000;14:17-23. (Pubitemid 30078429)
4. Pallis AG, Karampeazis A, Vamvakas L et al. Efficacy and treatment tolerance in older patients with NSCLC: a meta-analysis of five phase III randomized trials conducted by the Hellenic Oncology Research Group. Ann Oncol (2011)doi: 10.1093/annonc/mdq772
5. Balducci L. Geriatric oncology: challenges for the new century. Eur J Cancer 2000; 36: 1741-1754. (Pubitemid 30639493)
6. Wedding U, Honecker F, Bokemeyer C, Pientka L, Höffken K. Tolerance to Chemotherapy in Elderly Patients With Cancer. Cancer Control 2007; 14: 44-56.
7. Kohne CH, Folprecht G, Goldbegr R, Mitry E, Rougier P. Chemotherapy in elderly patients with colorectal cancer. The Oncologist 2008;13:390-402.
8. Jessup JM, Stewart A, Greene FL et al. Adjuvant chemotherapy for stage III colon cancer: implications of race/ethnicity, age, and differentiation. JAMA 2005;294:2703-2711. (Pubitemid 41770099)
9. Sundararajan V, Hershman D, Grann VR et al. Variations in the use of chemotherapy for elderly patients with advanced ovarian cancer: a population-based study. J Clin Oncol 2002; 20:173-178. (Pubitemid 34032609)
10. Mortimer J. Cancer in the elderly. ASCO Medical Oncology Self Evaluation Program, 2nd edition, 2010, 445.
11. Berardi R, Saladino T, Mari D et al. Elderly patients with advanced colorectal cancer: Tolerability and activity of chemotherapy. Tumori 2005; 91: 463-466. (Pubitemid 43251114)
12. Emperador PE, Marques EP, Orduna VA. Treatment of metastatic colorectal cancer in the elderly. Cancer Chemother Rev 2011;6: 154-159.
13. Saif MW. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer. Ann Gastroenterol 2012;25: 1-2.
14. Saif MW. Lichtman SM. Chemotherapy options and outcomes in older adult patients with colorectal cancer. Crit Rev Oncol Hematol 2009;72:155-169.
15. Folprecht G, Cunningham D, Ross P et al. Efficacy of 5-fluorouracil-based chemotherapy in elderly patients with metastatic colorectal cancer: A pooled analysis of clinical trials. Ann Oncol 2004; 15:1330-1338. (Pubitemid 39302467)
16. Eisenhauer EA, Therasseb P, Bogaert J et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) Eur J Cancer 2009;45:228-247.
17. Lewis JH, Kilgore ML, Goldman DP et al. Participation of patients 65 years of age or older in cancer clinical trials. J Clin Oncol 2003; 21: 1383-1389. (Pubitemid 46606420)
18. Balducci L, Extermann M. Management of cancer in the older person: A practical approach. The Oncologist 2000;5:224-237. (Pubitemid 30429942)
19. Popescu RA, Norman A, Ross PJ et al. Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 1999; 17: 2412-2418. (Pubitemid 29368240)
20. Jacobson SD, Cha S, Sargent DJ et al. Tolerability, dose intensity, and benefit of 5FU-based chemotherapy for advanced colorectal cancer (CRC) in the elderly. A North Central Cancer Treatment Group (NCCTG) study. Proc Am Soc Clin Oncol 2001; 20: 587 (abstr).
21. de Gramont A, Bosset JF, Milan C et al. A randomized trial comparing monthly low-dose leucovorin/fluorouracil bolus with bimonthly high-dose leucovorin/fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study. J Clin Oncol 1997; 15: 808-815. (Pubitemid 27074252)
22. Weh HJ, Zschaber R, Braumann D et al. A randomized phase III study comparing weekly folinic acid (FA) and high dose 5-fluorouracil (5-FU) with monthly 5-FU/FA (days 1-5) in untreated patients with metastatic colorectal carinoma. Onkologie 1998; 21: 403-407. (Pubitemid 28536434)
23. Kohne CH, Wils J, Lorenz M et al. Randomized phase III study of high dose 5-fluorouracil given as a weekly 24 hour infusion with or without leucovorin vs. bolus 5-fluorouracil plus leucovorin in advanced colorectal cancer. J Clin Oncol 2003; 21: 3721-3728. (Pubitemid 46606225)
24. On behalf of the Advanced Colorectal Cancer Meta-analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992; 10: 896-903.
25. Seymour MT, Thompson LC, Wasan HS et al. Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial. Lancet 2011;337:1749-1759.